Allergy medicine may help reinvigorate immunotherapy to treat lung cancer healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
<p style="text-align:justify">Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of <em>non-small cell lung cancer (</em>NSCLC)<em>. </em> And in an early parallel study in humans, combining immunotherapy with dupilumab<em>—</em>an <a href="https://www.frontiersin.org/articles/10.3389/fimmu.2018.00888/full" target=" blank">Interleukin-4</a> (IL-4) receptor-blocking antibody widely used for treating allergies and asthma<em>—</em>boosted patients' immune systems, with one out of the six experiencing significant tumor reduction. The findings were described in the December 6 issue of<em> Nature.</em></p>
/PRNewswire/ Riboscience, LLC, today announced the first presentation of data from the ongoing Phase 1 clinical trial of the ENPP1 inhibitor RBS2418 that.
The addition of an mRNA-based cancer vaccine to pembrolizumab extended RFS among patients with resected high-risk melanoma, according to study results presented at American Association for Cancer Research Annual Meeting.The benefit with the combination persisted regardless of patients’ tumor mutational burden status, findings of the randomized phase 2B KEYNOTE-942 trial showed.